Integral Investment Advisors Inc. Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Integral Investment Advisors Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 15.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,513 shares of the biopharmaceutical company’s stock after purchasing an additional 2,649 shares during the quarter. Integral Investment Advisors Inc.’s holdings in Pfizer were worth $562,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Worth Asset Management LLC bought a new position in Pfizer in the first quarter valued at about $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $30,000. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer in the 3rd quarter worth $34,000. Finally, VisionPoint Advisory Group LLC lifted its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE traded down $0.07 during trading on Thursday, hitting $25.35. 27,660,071 shares of the stock traded hands, compared to its average volume of 42,353,340. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.56. The firm has a 50-day simple moving average of $27.19 and a 200-day simple moving average of $28.76. The company has a market capitalization of $143.55 billion, a P/E ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the company posted $1.14 EPS. The business’s revenue was down 41.3% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.